Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 Mice

Iranian Biomedical Journal

Volumn 18, Issue 1, 2014, Pages 1-7

  Gorzin, Zahra ^a   Gorzin, Ali Akbar ^b   Tabarraei, Alijan ^c   Behnampour, Naser ^c   Irani, Shiva ^a   Ghaemi, Amir ^c,d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Khatam Al Anbia Hospital   (Iran)

Author keywords

DNA vaccine; Hepatitis C virus (HCV); IL 12; NS2 protein

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; LACTATE DEHYDROGENASE; NONSTRUCTURAL PROTEIN 2; NS2 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NS2 GENE; NUCLEOTIDE SEQUENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL PROLIFERATION; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; CELL PROLIFERATION; FEMALE; HEPACIVIRUS; HEPATITIS C; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84888408660     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: 10.6091/ibj.1231.2013     Document Type: Article

References (35)

1. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012 Jan; 54(1):96-104.
2. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol. 2005 Sep; 79(17):11095-11104.
3. Dumoulin FL, von dem Bussche A, Li J, Khamzina L, Wands JR, Sauerbruch T, et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology. 2003 Jan; 305(2): 260-266.
4. Jirasko V, Montserret R, Lee JY, Gouttenoire J, Moradpour D, Penin F, et al., Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog. 2010 Dec; 6(12):e1001233.
5. Popescu CI, Callens N, Trinel D, Roingeard P, Moradpour D, Descamps V, et al., NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog. 2011 Feb; 7(2):e1001278.
6. Gorzin AA, Ramsland PA, Tachedjian G, Gowans EJ. Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. J Viral Hepat. 2012 Mar; 19(3):189-198.
7. Yi M, Ma Y, Yates J, Lemon SM. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog. 2009; 5(5):e1000403.
8. Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, Lemon SM, et al., Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol. 2011 Jan; 85(1):86-97.
9. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011 Feb; 17(2):107-115.
10. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature, 2005. 436(7053):961-6.
11. Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol. 1998 Vov; 161(9):4917-4923.
12. Hilleman MR. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci U S A. 2004 Oct; 101 Suppl 2:14560-14566.
13. Duenas-Carrera S. DNA vaccination against hepatitis C. Curr Opin Mol Ther. 2004 Apr; 6(2):146-150.
14. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, et al., Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin. 2009 Mar; 5(3):151-157.
15. Lauer GM, Chung RT. Vaccine-induced T-cell responses against HCV: one step taken, more to follow. Gastroenterology. 2007 Apr; 132(4):1626-1628.
16. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, et al., Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat. 2009 Mar; 16(3):156-167.
17. Sallberg MM, Frelin L, Diepolder H, Jung MC, Mathiesen I, Fons M, et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. J Hepatol. 2009 Apr; 50:S18-S19.
18. Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol. 1999 Mar; 162(5):2912-2921.
19. Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE, et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther. 2003 Oct; 14(15):1389-1399.
20. Shubeita HE, Sambrook JF, McCormick AM. Molecular cloning and analysis of functional cDNA and genomic clones encoding bovine cellular retinoic acid-binding protein. Proc Natl Acad Sci U S A. 1987 Aug; 84(16):5645-5649.
21. Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, et al. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis. 2007 Jul; 30(4):197-210.
22. Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, Razavinikoo SMH. Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology. 2011; 54(3):105-112.
23. Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett. 2009; 16(7):842-850.
24. Kwon SS, Kim N, Yoo TJ. The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy. 2001 Aug; 56(8):741-748.
25. Geissler M, Gesien A, Tokushige K, Wands JR, Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol. 1997 Feb; 158(3):1231-1237.
26. Hu GJ, Wang RY, Han DS, Alter HJ, Shih JW. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine. 1999 Aug; 17(23-24):3160-3170.
27. Geissler M, Tokushige K, Wakita T, Zurawski VR Jr, Wands JR. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine. 1998 May; 16(8):857-867.
28. Lee SW, Cho JH, Lee KJ, Sung YC. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol Cells. 1998 Aug; 8(4):444-451.
29. Cho JH, Lee SW, Sung Y. Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine. 1999 Mar; 17(9-10):1136-1144.
30. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009 Jun; 113(23):5868-5877.
31. Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MG, Talbott K, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther.2010 Sep; 18(9):1714-1723.
32. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996 Jan; 4(1):25-36.
33. Tsuji T, Hamajima K, Fukushima J, Xin KQ, Ishii N, Aoki I, et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol. 1997 Apr; 158(8):4008-4013.
34. Tan J, Yang NS, Turner JG, Niu GL, Maassab HF, Sun J, et al. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther. 1999 Jul-Aug; 6(4):331-339.
35. Stevceva L, Moniuszko M, Ferrari MG. Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants. Lett Drug Des Discov. 2006; 3(8):586-592.